Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune ...

Shares of Moderna jumped more than 8% in the extended session Tuesday as the pharmaceutical company said it has reached a ...

Scientific, political pressures colliding at FDA, delaying rare disease treatment for patients who have few or no options, experts said at CNBC Cures Summit.

Jason Kelly, chief executive of Ginkgo Bioworks, spent a surprising amount of time on an earnings call with analysts last ...

Shares of Moderna jumped more than 11% in the extended session Tuesday as the pharmaceutical company said it has reached a deal to resolve a dispute related to its COVID vaccine.

TrialAssure announced today announced the launch of its AI in Medical Writing Certification (AIMWC) Program, a new ...

A long overdue reckoning for Henrietta Lacks — the Black woman whose cancer cells led to breakthroughs in the field but were harvested without her consent — has been slow but steady in recent years.

Perrigo announced they will lay off roughly 7% of its current workforce as part of a new two-year, enterprise-wide ...

Australia is a critical and growing hub for clinical research, and this investment allows us to support our customers ...

Anbio Biotechnology continues pivoting toward better profitability metrics, prioritized high-margin orders over sales volume. Read more on NNNN stock here.

Ann Arbor-based drug maker Esperion Therapeutics Inc. announced Tuesday it signed a definitive agreement to acquire Nevada-based biopharmaceutical company Corstasis Therapeutics.